Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1969-9-22
|
pubmed:language |
por
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0018-5469
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
75
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1343-55
|
pubmed:dateRevised |
2008-7-16
|
pubmed:meshHeading |
pubmed-meshheading:5306426-Adult,
pubmed-meshheading:5306426-Female,
pubmed-meshheading:5306426-Hematologic Diseases,
pubmed-meshheading:5306426-Hodgkin Disease,
pubmed-meshheading:5306426-Humans,
pubmed-meshheading:5306426-Leukemia,
pubmed-meshheading:5306426-Male,
pubmed-meshheading:5306426-Sulfinpyrazone,
pubmed-meshheading:5306426-Uric Acid
|
pubmed:year |
1969
|
pubmed:articleTitle |
[Effect of sulfinpyrazone(Anturan) on the uric acid metabolism in malignant blood diseases].
|
pubmed:publicationType |
Journal Article
|